APOE and achalasia-alacrima syndrome: Ang II infusion for 4 weeks caused AAAs in 71.4% (15/21) of ApoE-/- mice, whereas only 35.0% (7/20) of ApoE-/- mice administered ABT263 orally developed AAAs after Ang II infusion (Fig. 3A-B).